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In this review we summarize the ﬁndings from the literature and our own laboratory on the decreased PON1 activity in
renal failure, the mechanisms proposed and the eﬀect of interventions. In addition to profound alterations in lipoproteins,
reduced serum PON1 activity has been clearly established in the past decade and could contribute to accelerated development
of atherosclerosis in ESRD and in HD. PON1 lactonase activity is lower in ESRD patients. Hemodialysis partially restores PON1
lactonase and the other activities. PON1 activity recovery after dialysis suggests that uremic toxins may play a mechanistic role in
PON1 inactivation. Lower PON1 activity in CRF patients is associated with low thiol concentration, high CRP, and is beneﬁcially
enhanced with vitamin C and ﬂavonoids. Changes in HDL subclasses, namely lower HDL3 in these patients may also play a role
in PON1 lower activity. Future research should focus on: (1) mechanistic studies on causes for low PON1 activity and mass; (2)
prospective studies focusing on whether there is an added predictive value in measuring PON1 activity (and PON1 activity in
HDL3) in this patient population; (3) intervention studies attempting to increase PON1 activity.
1.Introduction
The major cause of mortality in patients with end-stage renal
disease (ESRD) receiving renal replacement therapy is car-
diovascular disease. More than one million of these patients
throughout the world are surviving with the assistance of
renal replacement therapy [1–8]. More than 800,000 patients
receive hemodialysis (HD), the most frequent modality.
Survival on HD has improved, although vascular accidents,
such as ischemic heart disease and hemorrhagic stroke,
remain major problems [2, 7, 8]. All patients with chronic
renal failure (CRF) have increased risk for death from car-
diovasculardisease,especiallythoseundergoingHD[1,2,9].
Theyhavenumerousmetabolicdisordersthatmayhastenthe
development of plaques, such as insulin resistance, hyper-
tension, and dyslipoproteinemia, along with other ESRD-
related risk factors such as the classical calcium and phos-
phate metabolism disorders and secondary hyperparathy-
roidism [1–9]. CRF patients frequently have lipoprotein
abnormalities such as low high-density lipoprotein (HDL)-
cholesterol concentrations, increased remnant particles and
hypertriglyceridemia. HDL-cholesterol concentrations are
inversely correlated with atherogenic risk [3, 4, 6, 7].
HDL is not only a key player in reverse cholesterol trans-
port but has the ability to protect low-density lipoprotein
(LDL) against oxidation, is an anti-inﬂammatory mediator,
protects the endothelium, and modulates coagulation [10–
14]. There is mounting evidence that paraoxonase 1 (PON1)
could be implicated in several of these processes, as shown
in detail elsewhere in this special issue of this journal
[15–26]. Human PON1 (aryldialkylphosphatase, EC 3.1.8.1)
is an esterase associated with apolipoprotein AI (apoAI)
and clusterin (apolipoprotein J) in HDL. PON1 displays
paraoxonase and arylesterase activities since it hydrolyzes
organophosphate compounds such as paraoxon, and aro-
matic carboxylic acid esters such as phenylacetate. PON1
possesses peroxidase-like activity that can contribute to its
protective eﬀect against lipoprotein oxidation [22, 27]. It2 Journal of Lipids
also displays homocysteine-thiolactonase activity that may
be linked with its antiatherogenic properties [28, 29]. PON1
protects lipids in lipoproteins, macrophages and erythro-
cytes from oxidation [30–32]. Together with its antiox-
idative properties, PON1 has added antiatherogenic activ-
ities against macrophage foam cell formation: reduc-
tion of cholesterol and oxidized lipids inﬂux, inhibition
of macrophage cholesterol synthesis, and stimulation of
macrophage cholesterol eﬄux [30–32]. However, the mech-
anism of PON1’s protective action and its endogenous
substrateremainelusive.Evidenceisaccumulatingindicating
that the lactonizing/lactonase activity of PON1 may be
physiologically the most signiﬁcant. Lactonase activity is
exerted on oxidized phospholipids and on homocysteine-
thiolactone [33–37] Hyperhomocysteinemia, encompassing
also higher concentrations of homocysteine-thiolactone, is
common in both ESRD and in patients on dialysis and may
be an added risk factor for enhanced atherogenesis.
In the past decade, much progress has been made on
PON1 status in patients with renal failure. Several case-
control studies have addressed the changes in PON1 activity
a n dm a s sa sw e l la sp r e v a l e n c eo fp o l y m o r p h i s m s .T h e
eﬀect of therapeutic modalities of intervention on PON1
activity has been explored: hemodialysis versus conservative
treatment; hemodialysis and transplant; peritoneal dialysis;
diﬀerent types of dialysis membranes; erythropoietin; vita-
min C and quercetin.
In this paper, we summarize the ﬁndings from the
literature and our own laboratory on the decreased PON1
activity in renal failure, the mechanisms proposed, and the
eﬀect of interventions. A bird’s eye view of the main ﬁndings
is presented on Figure 1.
2.PON1 Activityis Lowerin
ChronicRenal Failure
In1998, two groups ﬁrst studied PON1 activity in patients
with CRF as compared to control subjects. In one of
these studies, 119 hemodialyzed CRF patients, 107 patients
with primary hyperlipoproteinemia, and 110 healthy control
subjects were recruited and studied. PON1 activity was
signiﬁcantly lower both in hyperlipidemic and renal failure
patients as compared with controls [38]. To assess whether
the reduction in PON1 activity was due to changes in
HDL and Apo-A1 levels, the authors standardized the
enzyme activity for HDL and Apo-A1 concentrations. The
standardized PON1 activity (paraoxonase/HDL ratio) was
also lower in the renal failure patients as compared with
hyperlipidemic patients and controls. The phenotypic dis-
tribution of paraoxonase was not diﬀerent in the patient
groups [38] .T h es a m ey e a r ,a n o t h e rg r o u pr e p o r t e das t u d y
on 305 patients with CRF, 47 patients with non-ESRD,
22 patients treated with peritoneal dialysis 104 patients
treated with hemodialysis, and 132 renal transplant patients
[39, 40]. Patients were compared with two groups of aged-
matched control subjects (n = 195). PON1 activity was
lower in patients with renal insuﬃciency (chronic renal
failure; chronic hemodialysis; chronic peritoneal dialysis)
than in control subjects. Renal transplantation seems to
restore PON1 activity. The same group then reported that
PON1 in renal failure patients is better activated by salt than
that of control subjects, suggesting qualitative changes in the
molecule [39, 40]. These ﬁndings have since been conﬁrmed
by several groups in multiple studies [41–49].
3. PON1 Concentration is Lower in
ChronicRenal Failure
The fact that PON1 activity is lower in the sera of CRF
patients is well established as stated above. This led to
multiple studies addressing the mechanism behind this
change. The ﬁrst issue to clarify is whether the PON1 protein
is also low, or it is only a qualitative aﬀect (inhibition or shift
in HDL composition). Serum PON1 concentrations were
measured in 81 patients undergoing hemodialysis and 103
age-matchedhealthysubjectsusinganenzymeimmunoassay
[50]. PON1 concentration was signiﬁcantly lower in the
patient group than the control group. There were no
signiﬁcantassociationsbetweenserumPON1concentrations
and the PON1 genetic polymorphisms, 55Leu/Met (L/M),
and 192Gln/Arg (Q/R). The concentration adjusted for
HDL-cholesterol or apolipoprotein A-I was also lower in the
patient group. Several other studies have since conﬁrmed
these ﬁndings in other series [50–52].
4.HemodialysisversusContinuous
Ambulatory PeritonealDialysis(CAPD),
ConservativeTreatment,Transplant
SeveralreportsareconsistenttoshowthatPON1activityand
mass is lower at predialysis in CRF patients under HD or
CAPDorothermodalities, withnodiﬀerencesbetweenthese
groups [42, 53]. Transplanted patients display no diﬀerences
with controls [49].
5. PON1 Polymorphisms PrevalenceDoes Not
Differ in ChronicRenal FailurePatientsand
ControlSubjects
The PON1 genetic polymorphisms of 192 Gln/Arg and 55
Leu/Met in the amino acid sequence are partly involved in
the PON1 enzyme activity. Namely, the 192 Gln/Arg QQ
homocygotes have much lower PON1 activities when mea-
sured with paraoxon and not so signiﬁcant with other sub-
strates. Therefore, it is important to investigate whether the
polymorphisms are associated with CRF, since a shift in the
prevalence may provide an explanation for the lower activity
found consistently in the aforementioned studies. Several
papers have addressed this issue, some employing molecular
biology techniques, some using functional phenotyping with
2substrates,andﬁnallysomeusingcombinedapproaches.In
2000,thetwopolymorphisms(192Gln/Argand55Leu/Met)
were assessed in 96 patients undergoing hemodialysis and
in 136 normal controls [52]. There was no diﬀerence in
the distribution of the two polymorphisms between patients
and controls, and in every subgroup classiﬁed by the
polymorphisms, both paraoxonase and arylesterase activitiesJournal of Lipids 3
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Figure 1:Paraoxonase1activityandfunctionarecompromisedinchronicrenalfailurepatients.Thisdiagramsummarizesthemainﬁndings
discussed in the text as reported during the past decade in the literature.
were lower in patients than in controls. This suggested that
the enzyme activities of PON1 decreased in hemodialysis
patients, independent of the genetic polymorphism [52]. In
another series, 74 HD patients and 92 control subjects were
studied. PON1 activity, PON1 genotype (55 and 192 PON1
allelic polymorphisms), and the lipid proﬁle, including
HDL subfractions, were reported [54]. HD patients had
decreased median PON1 activity, lower mean HDL, as
well as decreased mean HDL3 concentration. HDL retained
about 70% of serum PON1 activity, almost completely
carried (95%) by HDL3 [54]. Finally, PON1 activity was
signiﬁcantly lower in HD versus control subjects even after
matching for the allelic polymorphism, which did not diﬀer
from control subjects. In another recent study, researchers
measured PON activity in 377 hemodialysis patients using
the substrates 4-nitrophenylacetate and phenylacetate and
its variation over time [41]. The PON ratio was cal-
culated from 4-nitrophenylacetate-derived activity divided
by phenylacetate-derived activity. Frequency distribution of
the PON1 ratio showed three diﬀerent PON phenotypes.
74% of hemodialysis patients showed PON1 phenotype 1,
21% PON1 phenotype 2, and 5% PON1 phenotype 3.
They observed a signiﬁcant reduction of PON1 ratio with
increasing dialysis time [41]. This suggests that qualitative
changes in PON1 occur in a time-dependent manner, by
which changes in one activity are higher than in others.
Finally, a very recent study included 238 control subjects
and 263 hemodialyzed patients [55]. Genotype frequencies
were diﬀerent between two compared groups only for L55M
polymorphism, with control group having higher frequency
of MM genotype. Again, they conﬁrm that Q192R, L55M,
and −108C-T polymorphisms are not causal factors leading
to the lower PON1 activity in hemodialyzed patients [55].
Several other studies provide conﬁrmatory results [38, 56–
59].
6. InterventionStudies
6.1. Hemodialysis and Other Modalities Have Beneﬁcial Eﬀects
onPON1Activity. Hemodialysisisthemostfrequentmodal-
ity of treatment for ESRD patients. To a degree that depends
onthenatureofthemembraneemployed,HD,althoughlife-
saving, is prooxidative and has the potential of negatively
aﬀecting PON1 activity. Our laboratory undertook a series
of studies to address the eﬀect of HD on PON1 activity.
We enrolled 22 ESRD patients undergoing hemodialysis in
whom paired pre- and postdialysis samples were studied
along with 30 age-matched control subjects [46]. ESRD
patientsshoweda76% decreaseinPON1activityconﬁrming
previous reports. HD results in a signiﬁcant, consistent
increase in the activity of the antioxidant enzyme PON1,
which ranged from 4 to 40% of the predialysis value. HDL-
cholesterol, apoAI, free cholesterol (as a LCAT surrogate),
HDL-subclasses, and TG did not change signiﬁcantly after
dialysis [46]. Changes in PON1 activity display a good
correlation (r = 0.66, P<0.001) with rates in which
creatinine and urea are cleared suggesting that another
cause for the observed lower PON1 concentrations in CRF
is the retention of low-middle molecules (see below) and
demonstrate a positive eﬀect of hemodialysis in the delicate
oxidant-antioxidant state of these patients, that should be
weighed against other pro-oxidant eﬀects that have also been
shown to occur previously [46].
6.2. Eﬀect of Membranes. In a recent study, the question
whether HD membrane permeability has any inﬂuence on4 Journal of Lipids
PON1 activity was addressed [60]. Forty-seven HD patients
and 24 controls were enrolled. Blood samples were with-
drawn after completion of 4-week treatment for a low-ﬂux
and a high-ﬂux membrane. (TOS), total antioxidant status
(TAS), and paraoxonase and arylesterase activities were mea-
sured in blood samples of the patients and the controls. Total
oxidant status in HD patients (both types of membranes)
were higher than controls while total antioxidant status and
PON1 activity were lower in HD patients. There were no
signiﬁcant diﬀerences between “low-ﬂux” and “high-ﬂux”
membranesinregardtooxidativestressparametersorPON1
enzyme activities. Membrane permeability seems to have no
inﬂuence on oxidative stress parameters and PON1 enzyme
activities [60].
6.3. HD and HDL Anti-Inﬂammatory Properties. By remov-
ing uremic toxins, dialysis may reduce LDL inﬂammatory
and increase HDL anti-inﬂammatory properties. On the
other hand, as stated above, exposure to dialyzer membrane
tubing and impurities from dialysate could amplify LDL
and HDL inﬂammatory activities. A recent study examined
the eﬀect of hemodialysis on LDL and HDL inﬂammatory
activities [61]. ESRD patients had increased LDL chemotac-
tic activity, reduced HDL anti-inﬂammatory activity, PON1
and glutathione peroxidase levels, and elevated plasma IL-
6 before dialysis. Hemodialysis reduced LDL inﬂammatory
and increased HDL anti-inﬂammatory activities. The bene-
ﬁcial eﬀects of hemodialysis are in part mediated by heparin,
which bears antioxidant lipolytic properties [61]. However,
another study shows no diﬀerence in the ratio PON1/HDL
in hemodialysis patients [62].
6.4. Vit C. In a study with 42 ESRD in HD and 50 control
subjects, CRF patients treated with vitamin C showed an
increase of PON1 activity and a decrease of AGE and lipid
hydroperoxides levels [63].
6.5. Quercetin and Cathechins. In a study with using
the model of renal failure induced by ethylene glycol,
it was reported that treatment impaired kidney compo-
sition, increased oxidative damage, and decreased serum
paraoxonase and arylesterase activities [64]. Quercetin and
cathechins enhanced antioxidant defenses—superoxide dis-
mutase and PON1 activities, reducing oxidative damage
suggesting that PON1 mediates the protective eﬀects of
ﬂavonoids against kidney damage by oxidative stress [64].
6.6.EPO. Theeﬀectsoftreatmentofanemiawithexogenous
recombinant erythropoietin (EPO) beta and iron on levels of
antibodies against oxidized low-density lipoproteins as well
as on serum PON1 activity and concentration were studied
in 49 predialysis patients with chronic renal disease [45].
After 6 months of treatment, compared with pretreatment
values, the median levels of serum PON1 activity was slightly
but signiﬁcantly increased and the concentration of PON1
was signiﬁcantly decreased. EPObeta and iron treatment of
anemia of CRF promotes changes in serum PON1 activity
andconcentrationthatsuggestabeneﬁcialeﬀectonoxidative
stress.
7. LactonaseActivityof PON1 IsLower in
ESRDPatients andIsRestored by HD
As stated before, PON1catalyzes the hydrolysis of numerous
substrates: lactones, thiolactones, esters, and phosphotri-
esters, including paraoxon, from which its misleading name
is derived. Nevertheless, a consensus seems to be emerging
thatPON1mainphysiologicalactivityisactingasalactonase
[28, 65–72]. Findings reporting changes in the promiscuous
esteraseactivitiesmaynotreﬂectchangesinthephysiological
function. Indeed, the substrate docking moieties around the
active site of PON1 diﬀer for each major category of sub-
strates, namely, the lactonase activity depends on a diﬀerent
region than the esterase activity [69, 73]. All of the studies
reported above, including our own, had not employed
lactones as substrates. In a study with 42 ESRD in HD and
49 control subjects, we found that our patients showed a
signiﬁcant 11% decrease in PON1 lactonase activity [74].
When we compared pre- and postdialysis samples, lactonase
changed favorably as a result of dialysis, as did the other
activities. This is worthy of note, given the likelihood that
lactonase activity may be the most important physiological
atheroprotective function of PON1. ESRD patients may be
more susceptible to the harmful eﬀects of lipid peroxidation
than healthy subjects, lower serum lactonase activity would
delay catabolism of oxidized phospholipids in LDL and
oxidized macrophages, allowing more time for radical chain
reactions to inactivate apolipoproteins and cell membrane
proteins [74].
8.MechanismsProposed
8.1. Role of Uremic Toxins
8.1.1. AGEs. We have shown that HD results in a signiﬁcant,
consistent increase in the activity of the antioxidant enzyme
PON1. The eﬀect correlates with the eﬀectiveness of dialysis
to clear creatinine and urea. This strongly suggests that
elimination of some inhibiting low molecular factor may be
responsible in part for the recovery of PON1 activity. Uremic
toxins, therefore, may be putative mediators of PON1-
deﬁcientactivity.Kidneyfailurepatientshaveveryhighlevels
of advanced glycation endproducts; even more than diabetic
patients [75–78]. AGE residues are formed by the action of
carbonyls(glucose,methylglyoxal,andotherdicarbonyls)on
long- and short-lived cellular and extracellular proteins. Cel-
lular proteolysis forms AGE-peptide and AGE-free adducts
from these proteins, which are released into plasma for
urinaryexcretion[75–78].WhenwestudiedAGEsinourHD
patients, the clearance of low-molecular-weight AGEs after
hemodialysis explained 79% of the changes in PON1 activity
and are hence a much better predictor than creatinine
changes [46]. In vitro incubation of paraoxonase with serum
ultraﬁltrates showed a time- and concentration-dependent
inhibition of PON1 by the ultraﬁltrates, an inhibition that
is up to 3 times higher (from 8 to 24%) when CRF patients
are the source of the ultraﬁltrate [46]. We showed that HD
results in a signiﬁcant, consistent increase in the activity of
the antioxidant enzyme PON1. The eﬀect correlates withJournal of Lipids 5
the eﬀectiveness of dialysis to clear creatinine and urea, and
with the clearance of AGE adducts of low molecular weight.
This eﬀect was replicated in vitro, showing time and dose
dependency. Our results suggest that another cause for the
observed lower PON1 concentrations in CRF is the retention
of low-middle molecules and demonstrate a positive eﬀect
of hemodialysis in the delicate oxidant-antioxidant state of
these patients that should be weighed against other pro-
oxidant eﬀects that have also been shown to occur previously
[46]. If the hypothesis that AGEs are the main culprits is
proved in further research, this opens a putative therapeutic
avenue for AGE blockers in ESRD.
8.1.2. Acrolein. Renal failure patients share lower PON1
levels and high serum acrolein levels [79–81]. Acrolein is a
highlyreactiveairpollutantofhumanhealthconcern,chieﬂy
as it is major component of cigarette smoke and also has sev-
eral endogenous sources [79–81]. Acrolein oxidizes cysteine
and forms adducts with lysine and histidine through the
Maillard reaction, with deleterious consequences on protein
function. Since PON1 has a cysteine residue critical for its
antioxidant activity, which is moreover modulated by apoA-
I, we hypothesized that acrolein could also have deleterious
eﬀects on PON1 activity [82]. We have shown that acrolein
inhibits PON1 activity in HDL at micromolar concentra-
tions and this inhibition is cancelled by n-acetylcysteine
[82]. PON1 has 1 critical cysteine residue in its catalytic
hydrophobic pocket. The results suggest that in conditions
where local acrolein concentrations are elevated (atheroma
plaque, sites of lipoperoxidation), acrolein-mediated loss of
PON1 activity could be a plausible phenomenon. In a study
with 40 ESRD in HD and 40 control subjects we found
that our patients had a 3-fold increase in free acrolein when
compared to control subjects. When we compared pre- and
posthemodialysis samples, PON1 activity changed favorably
as a result of dialysis, conﬁrming our previous data [46, 82–
84]. On average, free acrolein was 32% lower in postdialysis
samples [82]. When we correlated the increments in PON1
activity resulting from the hemodialysis intervention, with
the corresponding decrements in free acrolein we found a
signiﬁcant correlation. Our results suggest that high acrolein
levels may in part be responsible for the low PON1 levels
found in ESRD [82].
8.2. HDL Composition and PON1 Association/Dissociation
8.2.1. HDL Composition. From the discussion above, it
is clear that a certain consensus is emerging, favoring a
multiprong explanation for PON1-deﬁcient activity in CRF.
Circulating inhibitors (uremic toxins and others) are likely
candidates, together with decreased PON1 protein paired
with qualitative changes in the molecule. Diﬀerences in allele
distribution do not seem to play a role. PON1 activity largely
depends on its association with apoAI and phospholipids in
HDL, although a minor, free form can be found. In turn,
HDL encompasses a wide range of particles with diﬀerent
sizes and diverse physiological functions. HDL subclasses
are not homogeneous in PON1 content and activity. Small
HDL3 contains most of this activity and carries most of the
antioxidant capacity [13]. As CRF is associated with changes
in HDL subclasses distribution and function, this may
be another factor that compounds the observed decreased
PON1 activity in these patients. However, reduced HDL
levelsinvivomayresultinreducedHDLantioxidantcapacity
in these patients. In a study with 74 patients in HD, it was
shown that mean HDL3 concentration is decreased [54].
Most of PON1 activity in HDL was carried (95%) by HDL3.
The authors suggest that a key determinant of PON1 activity
reduction in HD is the depressed HDL3 and not the genetic
PON1 polymorphism [54].
8.2.2. Free PON1 Is Not Higher in CRF Patients. Aviram’s
group has shown that free PON1 increases in diabetes
patients and that glycation of HDL promotes dissociation
of the enzyme from the particle [85–87]. They suggest that
this mechanism may contribute to the lower activity found
in these patients and to a dysfunctional more atherogenic
HDL particle. We tackled the question whether increased
free PON1 in CRF patients could be a reason for the lower
activity [83]. Other than the classical routine ﬁndings in
these patients, we conﬁrmed that both PON1 triesterase
and lactonase activities are reduced in ESRD patients on
hemodialysis. The free triesterase activity is larger than the
free lactonase activity in both populations [83]. Free PON1,
however, was not signiﬁcantly diﬀerent between the groups
and that was true for the activity against paraoxon and the
more physiological lactonase activity [83].
9. Associationwith Other Biomarkers
9.1. Thiols. P O N 1 ’ so n l yf r e es u l f h y d r y lg r o u pi sp r e s e n t
at Cys284 and is associated with its activity even when it
is not part of its active site; rather, it is part of a highly
conserved stretch that includes active site histidine-285 [69,
73, 88–90]. Modiﬁcation of the enzyme’s free sulfhydryl
group, such as via S-glutathionylation, leads to inactivation
[91, 92]. In a study with 71 hemodialyzed patients and
87 healthy individuals, hemodialyzed patients had lower
PON1 paraoxonase and arylesterase activity, concentrations
of HDL, HDL3, and HDL2 and concentration of free thiol
groups [55]. Decreased concentration of free thiol groups
in sera suggest that the free thiol group (Cys284) in PON1
might also be oxidized, which can aﬀect PON1 activity. In
another study with 48 CRF patients on chronic maintenance
hemodialysis, 41 patients on conservative management and
41 age-matched controls, serum PON1 activity correlated
positively with protein thiols, and negatively with lipid
hydroperoxides [93].
9.2.Ischemia-ModiﬁedAlbumin(IMA). Theamino-terminal
end of albumin binds transitional metals such as cobalt.
When a speciﬁc motif (DAKK motif) in the N-terminus
is damaged, this results in a reduced binding capacity for
transitional metals [94–98]. This ischemia-modiﬁed albu-
min is formed in ischemic capillary beds as found in CVD,
especially in the acute coronary syndromes, and has also
been recently documented in patients with diabetes mellitus,
hyperlipidemia, and metabolic syndrome [94–98]. Recently,6 Journal of Lipids
prospective studies on CVD outcomes in ESRD using the
new biomarkers of HDL dysfunction and/or oxidative stress,
PON1 and IMA, have appeared in the literature [99–104].
In a pilot study, we explored this relationship in a small
cohort of HD patients with ESRD [84]. We showed that
PON1 levels were signiﬁcantly and inversely correlated with
IMA levels in these patients while such a clear correlation
was not found in non-ESRD controls. An inverse correlation
between PON1 and IMA levels indicate that low PON1
activity in these patients produces increased oxidative stress,
leading to IMA formation. Monitoring serum PON1 and
IMA simultaneously might thus provide another useful tool
for the clinical pathologists as a prognostic biomarker of
CVD in ESRD patients [84].
9.3. Cystatin C. Serum cystatin C is an alternative, more spe-
ciﬁc marker of glomerular ﬁltration rate [57].In a study with
74 hemodialized, 171 renal transplanted patients, and 110
healthy controls, a negative correlation was found between
PON1 activity and cystatin C level [43]. Homocysteine
level correlated negatively with PON1 activity, and positively
with cystatin C level. OxLDL and lipoperoxide levels were
signiﬁcantly higher in the renal patients. Cystatin C may be
a good predictive factor for homocysteine levels but for the
antioxidant status in patients with renal failure [42, 43].
9.4. Cortical Thickness. In a study with 37 CRF patients and
18 controls, there was a positive correlation between renal
cortical thickness and HDL levels and PON1 activity [105].
9.5. CRP. PON1 arylesterase activity and mass, C-reactive
p r o t e i n( C R P ) ,c y s t a t i nC ,w e r em e a s u r e di n3 0C R Fp a t i e n t s
and 30 control subjects [42]. PON1 activity and mass were
inversely correlated with CRP in HD patients. The grouping
of increased CRP and reduced PON1 may detect subjects at
higher risk for cardiovascular complications [42, 106].
10.PredictiveValue
Results from the multiple case-control studies reported in
this paper provide substantial evidence that renal failure
is associated with deﬁcient PON1 activity and mass that
are independent of changes in HDL-C. Evidence from
prospective studies is more scarce but encouraging. One of
these studies measured PON1 activity, concentration, and
genetic polymorphisms with an interval of 6 years in 81 HD
patients [51]. The relation between baseline cardiovascular
risk factors and clinical events was investigated. During fol-
lowup for 6 years, 42 deaths were recorded, including 24 fatal
cardiovascular events. In univariate analyses, baseline PON1
concentration was associated with not only cardiovascular
mortality, but also all-cause mortality during the period of
follow-up, as were age, preexisting cardiovascular disease,
and hemoglobin concentration [51]. In multivariate Cox
regression analysis, PON1 concentration retained signiﬁcant
associations with cardiovascular mortality and all-cause
mortality even after adjustment for other risk factors for
CVD or mortality in HD patients. Signiﬁcantly increased
cardiovascular mortality and all-cause mortality were shown
in the patients with low PON1 concentrations in Kaplan-
Meier survival curves, suggesting that low PON1 concen-
tration may be an independent predictor of cardiovascular
mortality in maintenance HD patients [51]. In another study
with 30 CRF patients undergoing HD, 30 patients with CRF
under conservative treatment, and 30 healthy controls, basal
PON1, salt-stimulated PON1 and arylesterase activities were
lower in patients than controls [44]. Carotid intima-media
thickness (IMT) was signiﬁcantly higher in HD than in
other CRF patients and both were signiﬁcantly higher than
controls. Linear regression showed that the most signiﬁcant
determinant of carotid IMT was PON1 arylesterase activity
in HD. Modifying this risk factor could be salutatory in this
patient population [44].
11. Conclusion
In addition to profound alterations in triglyceride, IDL-
and HDL-cholesterol concentrations, classical hallmarks of
renal failure, reduced serum paraoxonase activity has been
clearly established in the past decade and could contribute
to accelerated development of atherosclerosis in ESRD and
in HD. PON1 activity and mass has been found consistently
depressed in all studies papered. This is not due to associa-
tions of renal failure with speciﬁc phenotypes characterized
by lower activity against paraoxon. PON1 lactonase and
other activities all are the lower in ESRD patients. ESRD
patients may be more susceptible to the harmful eﬀects
of lipid peroxidation than healthy subjects. Hemodialysis
partially restores PON1 lactonase and the other activities.
An association between PON1 activity recovery after dialysis
has been found with creatinine changes, advanced glycation
end products, and acrolein suggesting that uremic toxins
may play a mechanistic role in PON1 inactivation. Lower
PON1 activity in CRF patients is associated with low thiol
concentration, high CRP, and is beneﬁcially enhanced with
vitamin C and ﬂavonoids. Changes in HDL subclasses,
namely, lower HDL3 in these patients may also play a role
in PON1 lower activity. Some studies indicate that PON1 has
an independent predictive value on CVD risk. These studies
lay the ground for future studies around three axes: (1)
mechanistic studies addressing the intimate explanation for
lowPON1activityandmass;(2)prospectivestudiesfocusing
on whether there is an added predictive value in measuring
PON1 activity (and PON1 activity in HDL3) in this patient
population; (3) intervention studies attempting to increase
PON1 activity, studying outcomes providing information on
eﬀective delay in the progression of atherosclerosis.
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